Eye Diseases > Retina
Age-Related Macular Degeneration
Evidence-based assessment and management of age-related macular degeneration. Comprehensive guide covering AREDS classification, pathogenesis, diagnosis, anti-VEGF therapy, and AREDS2 supplementation protocols for optometry practice.
Fundus view showing hallmark features of AMD. Soft drusen (yellow deposits) encircle the macula — characteristic of early/intermediate AMD. Geographic atrophy (pale grey ellipse) represents late dry AMD with RPE and photoreceptor loss. Subretinal haemorrhage and CNV/subretinal fluid (dashed arc) indicate wet/neovascular AMD requiring urgent anti-VEGF treatment.
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in people over 50 years of age in high-income countries. It is a progressive, bilateral disease of the macula, resulting from a complex interaction of genetic predisposition, complement dysregulation, oxidative stress, and ageing of the retinal pigment epithelium (RPE) and Bruch's membrane.
AMD is classified into early AMD (small/intermediate drusen), intermediate AMD (large drusen or non-central geographic atrophy), and late AMD. Late AMD subdivides into geographic atrophy (dry AMD — slow photoreceptor loss) and neovascular AMD (wet AMD, nAMD — choroidal neovascularisation causing rapid central vision loss).
The strongest risk factors are advanced age, smoking, and genetic polymorphisms in CFH and ARMS2/HTRA1. AREDS2 supplementation (vitamins C, E, lutein, zeaxanthin, zinc, copper) reduces progression to late AMD by ~25% in intermediate AMD. Intravitreal anti-VEGF agents (aflibercept, faricimab, brolucizumab, ranibizumab) are first-line treatment for nAMD, preserving or improving vision in approximately 90% of treated eyes when started promptly.
Most common cause
Blindness >50 yrs
Prevalence at 75+
~30%
Strongest modifiable risk
Smoking
nAMD treatment
Anti-VEGF (T&E)
AMD is multifactorial, with age as the dominant driver. No single cause is identified in any individual patient.
Age
Most important risk factor; prevalence rises sharply after 60. The ageing RPE loses capacity for proteolytic clearance of oxidative debris, leading to drusen accumulation.
Smoking
Doubles AMD risk; dose-dependent relationship; strongest single modifiable risk factor. Cessation reduces risk over time but never fully eliminates elevated risk.
Genetic polymorphisms
CFH (complement factor H) Y402H variant — accounts for ~50% of AMD genetic risk. ARMS2/HTRA1 (chromosome 10q26) — second major locus; associated with aggressive nAMD. C3, C2/CFB, CFI variants also contribute to complement dysregulation.
Family history
First-degree relative with AMD confers 3–4× increased lifetime risk; reflects shared genetic and environmental factors.
Cardiovascular disease / hypertension
Associated via shared pathways of endothelial dysfunction, inflammation, and oxidative stress. Shared vascular risk factors link AMD and atheromatous disease.
Diet and nutrition
Low dietary antioxidants (vitamins C, E), low lutein/zeaxanthin, and low omega-3 fatty acid intake are associated with increased AMD risk. Basis for AREDS2 supplementation rationale.
Ethnicity
Caucasian/European populations have higher AMD prevalence than East Asian or African-origin populations. Asian populations have higher rates of polypoidal choroidal vasculopathy (PCV), a subtype of nAMD.
Female sex
Higher AMD prevalence after age 75, partly due to longer life expectancy; possible oestrogen-related vascular effects.
UV/light exposure
Contributory but lower evidence than smoking or genetics. Chronic cumulative blue-light and UV exposure may accelerate lipofuscin accumulation in RPE.
AMD pathogenesis involves progressive RPE dysfunction driven by oxidative stress, complement dysregulation, and Bruch's membrane thickening, with divergent pathways for dry and wet forms.
- 1Accumulation of oxidative metabolic by-products in the RPE — lipofuscin (A2E), complement activation fragments, and advanced glycation end-products build up with ageing.
- 2Bruch's membrane thickens with age; lipid-protein deposits (basal linear deposits and drusen) accumulate between the RPE basement membrane and Bruch's inner collagenous layer.
- 3Chronic complement system dysregulation (especially the alternative complement pathway, amplified by CFH/ARMS2 polymorphisms) → localised sub-RPE inflammation → RPE dysfunction and loss.
- 4Drusen formation: lipid-rich deposits beneath RPE are the hallmark of early/intermediate AMD. Soft drusen ≥125 µm carry significantly higher risk of progression to late AMD than hard drusen.
- 5Dry AMD pathway: RPE atrophy progresses centrifugally → underlying photoreceptors degenerate → geographic atrophy (GA) develops. GA spreads at ~1.7 mm²/year on average, eventually involving the fovea and causing central vision loss.
- 6Wet AMD (nAMD) pathway: Hypoxia from RPE/Bruch's dysfunction → upregulation of VEGF-A → choroidal neovascularisation (CNV) → new pathological vessels breach Bruch's membrane → subretinal and/or intraretinal fluid, exudation, haemorrhage → rapid central vision loss if untreated.
- 7Anti-VEGF treatment suppresses CNV growth and fluid, but does not cure the underlying disease; sustained treatment prevents recurrence in most patients.
AREDS Classification (Age-Related Eye Disease Study)
| Stage | Features | 5-Year Risk to Late AMD |
|---|---|---|
| No AMD | No or few small drusen (<63 µm) | ~0.5% |
| Early AMD | Multiple small drusen or few intermediate drusen (63–124 µm); no late AMD | ~1.3% |
| Intermediate AMD | Extensive intermediate drusen, ≥1 large drusen (≥125 µm), or non-central GA; no late AMD | ~18% (1 eye) / ~26% (2 eyes) |
| Late AMD — GA (Dry) | Geographic atrophy of RPE involving or threatening fovea | N/A — already late AMD |
| Late AMD — nAMD (Wet) | Choroidal neovascularisation + associated exudation/haemorrhage/fluid | N/A — already late AMD |
CNV Classification (Gass / Fluorescein-based)
- Type 1 (occult CNV): CNV beneath RPE; poorly defined on FFA; slow leakage; often associated with PED
- Type 2 (classic CNV): CNV above RPE; well-defined hyperfluorescence on FFA; rapidly progressive; more exudation
- Type 3 (RAP — Retinal Angiomatous Proliferation): Intraretinal neovascularisation; bilateral; distinct intraretinal haemorrhage on OCT; requires ICGA for confirmation
- Polypoidal Choroidal Vasculopathy (PCV): AMD variant more common in Asian populations; polypoidal CNV lesions on ICGA; serosanguineous detachments; responds to combined anti-VEGF and PDT
Advanced age
Prevalence ~2% at age 50; ~30% at age 75+; most important non-modifiable risk
Smoking
Doubles AMD risk; dose-dependent; cessation reduces risk over time — most important modifiable risk factor
Genetic polymorphisms
CFH Y402H and ARMS2/HTRA1 — together account for majority of AMD genetic susceptibility
Family history
First-degree relative with AMD: 3–4× increased risk
Caucasian / European ethnicity
Higher prevalence than East Asian or African-origin populations
Cardiovascular risk factors
Hypertension, hyperlipidaemia, atherosclerosis — shared vascular pathways
Obesity (BMI >30)
Associated with nAMD progression; metabolic syndrome amplifies oxidative stress
Low antioxidant diet
Low lutein, zeaxanthin, omega-3 intake; high glycaemic index diet associated with AMD
Prior cataract surgery
Controversial; may unmask pre-existing AMD or increase light exposure to macula
Female sex
Higher age-adjusted prevalence after 75; possible hormonal contributions
Dry AMD (Early/Intermediate)
Drusen
Yellow-white subretinal deposits between RPE and Bruch's membrane. Hard drusen: small, discrete, well-defined (<63 µm). Soft drusen: larger (≥63 µm), confluent, ill-defined borders — higher progression risk. Distributed at and around the macula.
RPE hyperpigmentation
Focal dark pigment clumps at or near drusen; sign of RPE hyperplasia/hypertrophy; associated with increased nAMD risk.
RPE hypopigmentation / depigmentation
Pale patches as RPE cells thin and lose pigment; earliest precursor of geographic atrophy.
Geographic atrophy (GA)
Well-demarcated area of RPE atrophy and photoreceptor loss; choroidal vessels visible through atrophic RPE (ʻbare chorioʼ appearance); typically pericentral initially, sparing fovea until late-stage.
Wet AMD (nAMD)
Subretinal haemorrhage
Dark, irregular haemorrhage at or around the fovea; may be large; arises from CNV rupture; urgent sign requiring same-day ophthalmology referral.
Subretinal / intraretinal fluid
Grey-green elevation of neurosensory retina; loss of foveal light reflex; elevation from CNV leakage beneath or within the retina.
Hard exudates
Cream-yellow lipid deposits from chronic CNV leakage; circinate pattern around CNV; similar to diabetic exudates but in macular location.
Pigment epithelial detachment (PED)
Dome-shaped elevation of RPE; serous (clear fluid), drusenoid, or fibrovascular types; fibrovascular PED at risk of RPE tear.
Disciform scar
End-stage nAMD: white-grey fibrovascular scar replacing CNV; permanent central scotoma; densely hyporeflective on OCT.
OCT findings
Subretinal fluid (SRF), intraretinal fluid (IRF), irregular RPE band, hyperreflective CNV membrane above (type 2) or below (type 1) RPE; drusenoid PED; ellipsoid zone disruption over GA.
Gradual central visual loss
Characteristic of dry AMD; slow decline over months to years; often bilateral but asymmetric; peripheral vision preserved throughout disease.
Rapid central visual loss
Hallmark of nAMD onset; onset over days to weeks; urgent red flag — requires same-day/next-day ophthalmology referral for anti-VEGF assessment.
Metamorphopsia
Straight lines appear wavy or distorted; classic nAMD symptom from subretinal fluid lifting the photoreceptor layer; Amsler grid positive; may also occur in GA.
Central scotoma
Dark, grey, or blurred area in central vision; first noticed for reading fine print or recognising faces; absolute scotoma in established GA or disciform scar.
Difficulty reading / fine detail tasks
Reduced letter resolution, contrast sensitivity, and reading speed; often first functional complaint; MNREAD score and contrast sensitivity testing document this.
Poor dark adaptation
Early sign even in drusen stage — RPE dysfunction impairs the visual cycle (11-cis-retinal regeneration); patients complain of difficulty in dim lighting.
Bilateral asymmetry
One eye typically worse; fellow eye may have drusen only and be asymptomatic; critical to examine and monitor the better eye at every visit.
Asymptomatic early AMD
Drusen found incidentally on routine examination; patient unaware of disease; important opportunity for AREDS2 counselling and lifestyle modification.
Legal blindness / severe central vision loss
GA involving the fovea or disciform scar from end-stage nAMD; affects independence for driving, reading, and facial recognition; peripheral vision preserved.
Bilateral late AMD
Up to 40% of nAMD patients develop wet AMD in the fellow eye within 5 years without treatment; requires vigilant monitoring of the fellow eye.
Vitreous haemorrhage
Rupture of fragile CNV vessels; sudden, profound visual loss; blood obscures view; B-scan ultrasound used to exclude retinal detachment; usually clears spontaneously.
Retinal pigment epithelial (RPE) tear
Occurs with large vascularised PEDs under mechanical stress; sudden vision loss; linear tear visible on OCT and fundus imaging; poor prognosis.
Disciform fibrovascular scar
End-stage nAMD; dense white-grey subretinal fibrovascular scar replacing active CNV; permanent, irreversible central loss; result of delayed or inadequate anti-VEGF treatment.
Depression and psychosocial impact
Significant loss of independence, quality of life, and social engagement; depression prevalence is 2–3× higher in AMD patients; screen at each visit and facilitate referral to low-vision services.
Low vision / rehabilitation needs
Eccentric viewing training, magnification aids, and assistive technology required as central vision deteriorates; referral to low-vision rehabilitation services is essential.
Cardiovascular disease
AMD and atherosclerosis share complement dysregulation, chronic inflammation, and oxidative stress pathways. AMD patients have increased cardiovascular morbidity. Managing CVD risk factors (BP, lipids, smoking) is beneficial for both conditions.
Systemic hypertension
Weakly associated with AMD progression through choroidal ischaemia and vascular endothelial damage. Blood pressure control is prudent but evidence for direct AMD benefit is limited.
Smoking / tobacco use
Strongest modifiable systemic risk for AMD. Nicotine impairs choroidal perfusion; oxidative metabolites from smoking accelerate RPE lipofuscin accumulation. Cessation counselling is essential at every AMD consultation.
Obesity and metabolic syndrome
Associated with nAMD progression; adipose-derived inflammatory cytokines and oxidative stress amplify complement activation. Weight management and regular exercise are recommended lifestyle interventions.
Statins
Uncertain direct benefit for AMD; not recommended specifically for AMD prevention. Appropriate for cardiovascular risk reduction; possible indirect benefit through reduction of systemic inflammation and lipid deposition.
Aspirin
Low-dose aspirin is not causative for AMD. Some studies suggest a weak association with conversion to nAMD in genetically susceptible individuals, but cardiovascular benefits of aspirin generally outweigh ocular risk. Do not discontinue aspirin for AMD alone.
Nutritional / dietary factors
Mediterranean-style diet (leafy greens, fish, nuts, reduced processed food) is associated with lower AMD risk and slower progression. AREDS2 supplements are evidence-based for intermediate/late AMD patients.
Slit-lamp biomicroscopy (90D/78D)
Essential for identifying drusen type and distribution, RPE changes (hyper/hypopigmentation), haemorrhage, retinal elevation suggesting PED or CNV. Retroillumination enhances drusen visibility. Required at every AMD visit.
OCT (gold standard for nAMD)
Identifies subretinal fluid (SRF), intraretinal fluid (IRF), PED type and height, CNV membrane location (type 1 vs 2), ellipsoid zone integrity, and GA extent. Guides treatment initiation and monitoring intervals. Most critical diagnostic and monitoring tool for AMD management.
Amsler grid
Detects and monitors metamorphopsia — patients self-administer at home. Daily home Amsler monitoring recommended for high-risk fellow eyes and treated nAMD eyes. May underestimate severity due to neural adaptation.
Fundus autofluorescence (FAF)
Maps RPE lipofuscin; soft drusen appear hyperAF; GA appears hypoAF with hyperAF junctional halo (predicts faster GA growth). Serial FAF quantifies GA growth rate. Integral to dry AMD monitoring.
Fluorescein angiography (FFA)
Characterises CNV type (classic/occult/mixed), activity, extent. RAP confirmation; PCV workup. Less essential in routine nAMD monitoring due to OCT availability, but still gold standard for PCV differentiation and FFA-guided decision making.
Indocyanine green angiography (ICGA)
Superior to FFA for choroidal lesions; definitive diagnostic tool for PCV (polypoidal lesions) and type 1 occult CNV. Essential for PCV diagnosis before combination anti-VEGF + PDT treatment.
OCTA (OCT angiography)
Non-invasive, dye-free CNV detection; flow signal within CNV network; increasingly used in place of FFA for monitoring treatment response and detecting subclinical CNV. Cannot quantify leakage.
Visual acuity (ETDRS/Snellen)
Baseline and at every anti-VEGF injection visit. Guides treatment response assessment. VA alone may underestimate functional impact — supplement with contrast sensitivity and reading speed.
Contrast sensitivity / reading speed
Often disproportionately reduced relative to Snellen VA in AMD; functional endpoints for clinical trials and counselling; MNREAD chart for reading speed.
1. Dry AMD / Geographic Atrophy
Observation and monitoring
Annual dilated fundus examination and OCT for intermediate and late dry AMD. Home Amsler grid monitoring. Prompt review for any new metamorphopsia or sudden vision change suggesting nAMD conversion.
AREDS2 supplementation
Indicated for intermediate AMD or late AMD in one eye. Formulation: Vitamin C 500 mg, Vitamin E 400 IU, Lutein 10 mg, Zeaxanthin 2 mg, Zinc 80 mg, Copper 2 mg. Reduces progression to late AMD by ~25% (AREDS2 RCT). NOT effective in early AMD or as primary prevention. Avoid beta-carotene in current or former smokers (increased lung cancer risk demonstrated in CARET trial).
Lifestyle modification
Smoking cessation (most important single intervention); Mediterranean-style diet rich in leafy greens, oily fish, nuts; weight management; regular exercise; UV-protective sunglasses.
Emerging GA treatment
Pegcetacoplan (Syfovre) — intravitreal complement C3 inhibitor; FDA approved 2023; reduces GA growth rate ~22% (OAKS/DERBY trials). Avacincaptad pegol (Izervay) — complement C5 inhibitor; also FDA approved 2023. Both require regular intravitreal injections and do not restore lost vision; role in routine clinical practice is evolving.
2. Wet AMD (nAMD) — Intravitreal Anti-VEGF (First-Line)
Aflibercept (Eylea) 2 mg
VEGF-Trap; 3 monthly loading doses then every 8 weeks; non-inferior to ranibizumab (VIEW 1/2); widely used. Eylea HD (8 mg) — approved 2023; every 12–16 week dosing after loading.
Faricimab (Vabysmo) 6 mg
Dual anti-VEGF + anti-Ang-2 bispecific antibody; every 12–16 week dosing (TENAYA/LUCERNE trials); extending intervals; increasingly preferred for lower injection burden.
Brolucizumab (Beovu) 6 mg
Single-chain anti-VEGF; every 8–12 week dosing (HAWK/HARRIER); monitor for intraocular inflammation and retinal vasculitis — discuss risk:benefit with patient.
Ranibizumab (Lucentis) 0.5 mg
First anti-VEGF approved for nAMD (MARINA/ANCHOR trials); monthly injections; ~90% no further VA loss; now less commonly used due to cost and newer extended-dosing agents.
Treat-and-extend (T&E) protocol
Preferred real-world strategy: injection at every visit; interval extended by 2 weeks if OCT is stable (no fluid), reduced if recurrence detected. Minimises injection burden while maintaining efficacy. Superior to PRN.
Pro re nata (PRN) strategy
Inject only if active fluid detected on OCT; monthly monitoring required. Inferior to T&E in maintaining visual gains — higher re-activation rates due to monitoring gaps.
Photodynamic therapy (PDT)
Historical first-line (TAP trial 2001); now limited to PCV (combined anti-VEGF + PDT — EVEREST II) and select type 1 classic/occult CNV. Not used as monotherapy for typical nAMD.
Singapore Optometry Scope Note
Optometrists in Singapore use fundus cameras and wide-field imaging to assess macular health and screen for AMD — dilated fundus examination is not within optometry scope of practice. OCT imaging, Amsler grid assessment, and non-mydriatic fundus photography are appropriate tools for AMD monitoring. AREDS2 supplement counselling and lifestyle advice (smoking cessation, diet, UV protection) are appropriate for intermediate AMD patients. Urgent referral to ophthalmology is required for any new or worsening metamorphopsia, sudden central visual loss, or imaging evidence of subretinal fluid suggesting nAMD conversion — same-day or next-day referral for acute nAMD presentations. Therapeutic-endorsed optometrists may manage co-existing ocular surface disease. Educate all AMD patients on daily Amsler grid self-monitoring and prompt reporting of new distortion.
Dry AMD (untreated)
Slow progression over years to decades. Most patients retain peripheral vision and ambulatory function throughout life. Bilateral GA involving the fovea leads to severe central vision loss but legal blindness from peripheral loss alone does not occur.
Geographic atrophy progression rate
Average ~1.7 mm²/year; junctional zone (hyperAF ring on FAF) area predicts faster progression. Foveal sparing is common until late stage. New complement inhibitors (pegcetacoplan, avacincaptad) reduce GA growth by ~20–22% but do not restore vision.
nAMD untreated
~70% of eyes lose ≥3 lines VA at 2 years; ~1/3 progress to legal blindness from disciform scar. Prompt treatment is critical — every week of delay in acute nAMD worsens visual outcome.
nAMD with anti-VEGF
~90% maintain or gain VA (no further loss); ~30–40% gain ≥3 lines ETDRS (MARINA/ANCHOR/VIEW). Requires sustained long-term treatment — most patients require lifelong injections to prevent recurrence.
Fellow eye risk
~40% of nAMD patients develop wet AMD in the fellow eye within 5 years without AREDS2 supplementation or monitoring. Active surveillance and AREDS2 supplementation are mandatory for the fellow eye.
Key favourable prognostic factors
Early diagnosis and prompt anti-VEGF treatment; intact ellipsoid zone pre-treatment; subfoveal lesion not too large; good baseline VA; high treatment adherence (T&E protocol); idiopathic (non-PCV) nAMD.
Key poor prognostic factors
Delayed treatment (>4 weeks from symptom onset to first injection); large baseline lesion size; RPE tear; disciform scar at presentation; poor treatment compliance; bilateral late AMD; concurrent geographic atrophy in treated eye.
| Condition | Key Differentiator |
|---|---|
| Central Serous Chorioretinopathy (CSCR) | Subretinal fluid without CNV; young-to-middle-aged men; RPE leak on FFA; self-limiting in most; no drusen; distinct from nAMD |
| Diabetic Macular Oedema (DMO) | Intraretinal fluid from diabetic vascular leakage; cystoid OCT pattern; no CNV; context of diabetic retinopathy; anti-VEGF responsive |
| Polypoidal Choroidal Vasculopathy (PCV) | AMD subtype more common in Asians; polypoidal lesions on ICGA; serosanguineous detachments; combined anti-VEGF + PDT preferred; requires ICGA for definitive diagnosis |
| Myopic CNV | High myopia; lacquer cracks, tilted disc, peripapillary atrophy; smaller CNV at fovea; anti-VEGF responsive; younger patients; distinct from AMD drusen |
| Angioid Streaks + CNV | Crack-like breaks in Bruch's membrane radiating from disc; associated with pseudoxanthoma elasticum, Paget's disease, sickle cell; CNV common complication |
| Pattern Dystrophy (PRPH2) | Hereditary; bilateral butterfly-shaped or vitelliform RPE deposits at fovea; mimics drusen; relatively benign; ERG/genetic testing confirms; onset younger than AMD |
| Best Disease (VMD2/BEST1) | Hereditary vitelliform macular dystrophy; BEST1 gene; egg-yolk lesion in young patients progressing to vitelliruptive/atrophic stages; EOG abnormal (reduced Arden ratio) |
| Stargardt Disease (ABCA4) | Autosomal recessive; juvenile/young adult onset; central atrophy + pisciform flecks throughout posterior pole; dark choroid on FFA; distinct FAF pattern |
| Choroidal Melanoma | Pigmented choroidal mass with overlying subretinal fluid; dome or mushroom shape; B-scan ultrasound; fundus mass vs flat AMD lesion; urgent ocular oncology referral |
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005-2015.
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
- Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-84.
- Khanani AM, Wykoff CC, Ciulla TA, et al. Efficacy of every four monthly and treat-and-extend dosing regimens with faricimab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(9):981-990.
- Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738.
- Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116.
- Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA. 1994;272(18):1413-1420.
- Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079-1091.
- Jaffe GJ, Westby K, Csaky KG, et al. C3-inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2021;128(4):576-586.
- Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4):844-851.
- Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147-1159.
- Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med. 2012;33(4):295-317.